PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22211244-1	2012	Inhibitors of lipid metabolic pathways, particularly drugs targeting the mevalonate pathway, have been suggested to be valuable in enhancing the effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and these compounds may also be effective in patients with inherent or acquired resistance to EGFR-TKIs.	Mevalonic Acid	73-83	epidermal growth factor receptor	Homo sapiens	223-227	
30106444-5	2018	Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor of the mevalonate pathway that inhibits YAP bioactivity through nuclear translocation and total YAP expression, increased the cytotoxicity of EGFR inhibitors (cetuximab and gefitinib) against CRC cells.	Mevalonic Acid	90-100	epidermal growth factor receptor	Homo sapiens	225-229	
30106444-7	2018	Adding back geranylgeranyl pyrophosphate (GGPP), a key product of the mevalonate pathway, reversed the YAP bioactivity inhibition induced by simvastatin and the cell proliferation inhibition induced by the combination of simvastatin and EGFR inhibitors.	Mevalonic Acid	70-80	epidermal growth factor receptor	Homo sapiens	237-241	
16857822-1	2006	Mevalonate metabolites play an essential role in transducing epidermal growth factor (EGF) receptor (EGFR)-mediated signaling, as several of these metabolites are required for the function of this receptor and the components of its signaling cascades.	Mevalonic Acid	0-10	epidermal growth factor receptor	Homo sapiens	61-99	
16857822-1	2006	Mevalonate metabolites play an essential role in transducing epidermal growth factor (EGF) receptor (EGFR)-mediated signaling, as several of these metabolites are required for the function of this receptor and the components of its signaling cascades.	Mevalonic Acid	0-10	epidermal growth factor receptor	Homo sapiens	101-105	
16857822-2	2006	Thus, the depletion of mevalonate metabolites may have a significant effect on EGFR function.	Mevalonic Acid	23-33	epidermal growth factor receptor	Homo sapiens	79-83	
15788691-0	2005	Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.	Mevalonic Acid	14-24	epidermal growth factor receptor	Homo sapiens	62-94	
15788691-4	2005	Mevalonate metabolites play significant roles in the function of the EGFR; therefore, mevalonate pathway inhibitors may potentiate EGFR-targeted therapies.	Mevalonic Acid	0-10	epidermal growth factor receptor	Homo sapiens	69-73	
15788691-4	2005	Mevalonate metabolites play significant roles in the function of the EGFR; therefore, mevalonate pathway inhibitors may potentiate EGFR-targeted therapies.	Mevalonic Acid	0-10	epidermal growth factor receptor	Homo sapiens	131-135	
15788691-4	2005	Mevalonate metabolites play significant roles in the function of the EGFR; therefore, mevalonate pathway inhibitors may potentiate EGFR-targeted therapies.	Mevalonic Acid	86-96	epidermal growth factor receptor	Homo sapiens	69-73	
15788691-4	2005	Mevalonate metabolites play significant roles in the function of the EGFR; therefore, mevalonate pathway inhibitors may potentiate EGFR-targeted therapies.	Mevalonic Acid	86-96	epidermal growth factor receptor	Homo sapiens	131-135	
15788691-8	2005	RESULTS: Lovastatin treatment inhibited EGF-induced EGFR autophosphorylation by 24 hours that was reversed by the coadministration of mevalonate.	Mevalonic Acid	134-144	epidermal growth factor receptor	Homo sapiens	52-56	
15788691-12	2005	CONCLUSIONS: Taken together, these results show that targeting the mevalonate pathway can inhibit EGFR function.	Mevalonic Acid	67-77	epidermal growth factor receptor	Homo sapiens	98-102	
12942316-11	2003	Mevalonate metabolites may regulate EGFR function, suggesting that lovastatin may inhibit the activity of this receptor.	Mevalonic Acid	0-10	epidermal growth factor receptor	Homo sapiens	36-40	
22211244-1	2012	Inhibitors of lipid metabolic pathways, particularly drugs targeting the mevalonate pathway, have been suggested to be valuable in enhancing the effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and these compounds may also be effective in patients with inherent or acquired resistance to EGFR-TKIs.	Mevalonic Acid	73-83	epidermal growth factor receptor	Homo sapiens	328-332	
22211244-3	2012	Gene expression correlation analysis showed that genes involved in the mevalonate pathway and unsaturated fatty acid synthesis were negatively correlated with the expression of EGFR, MET and other growth factor receptor genes, as well as with the expression of genes involved in cell migration and adhesion.	Mevalonic Acid	71-81	epidermal growth factor receptor	Homo sapiens	177-181	
20838437-1	2010	BACKGROUND: In a recent study, we demonstrated the ability of lovastatin, a potent inhibitor of mevalonate synthesis, to inhibit the function of the epidermal growth factor receptor (EGFR).	Mevalonic Acid	96-106	epidermal growth factor receptor	Homo sapiens	149-181	
20838437-1	2010	BACKGROUND: In a recent study, we demonstrated the ability of lovastatin, a potent inhibitor of mevalonate synthesis, to inhibit the function of the epidermal growth factor receptor (EGFR).	Mevalonic Acid	96-106	epidermal growth factor receptor	Homo sapiens	183-187